QuidelOrtho secures covenant relief as weak demand strains deleveraging

QuidelOrtho is trying to rebuild cash flow and reduce debt while dealing with weaker respiratory demand and a reset of its 2026 outlook; management had cut 2026 revenue guidance to $2.52–$2.60 billion from $2.70–$2.75 billion and withdrawn free-cash-flow guidance.

The amendment gives the company meaningful breathing room. It resets the financial covenants through September 30, 2029. 〔0〕

The relief is also a warning about the starting point. Compared with the prior agreement’s 4.50x leverage cap and 3.00x interest-coverage floor, the temporary 5.50x and 2.25x thresholds are materially looser. That does not change the debt balance, but it acknowledges that weaker earnings or cash generation could otherwise make compliance difficult. The company’s existing financing totals $3.4 billion across term loans and revolver capacity, including a $1.15 billion Term Loan A, $100 million delayed-draw facility, $1.45 billion Term Loan B and $700 million revolver.

This is runway, not a cure. Interest rates on the Term Loan A and revolver remain tied to leverage and can reach 3.00% over Term SOFR plus the applicable base spread, while the Term Loan B economics are unchanged. 〔1〕 The company also adds restrictions during the relief period, so flexibility is being purchased with tighter operating guardrails rather than through debt reduction.

Bottom line: The amendment reduces near-term covenant risk and gives QuidelOrtho time to repair cash flow, but it also confirms that leverage has become a central constraint. It matters because the company now has more runway, not because its underlying debt problem has been solved.